News und Analysen
EQS-News: Contract of Knorr-Bremse Executive Board member Nicolas Lange extended by five years
EQS-Adhoc: flatexDEGIRO AG: Full-year 2025 guidance raised following continued growth in the third quarter
EQS-News: Basler AG acquires majority stake in its distribution partner in India
EQS-Adhoc: Energiekontor AG: Energiekontor adjusts earnings forecast for 2025 financial year
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I
EQS-News: Energiekontor AG: SachsenEnergie acquires Würselen wind park from Energiekontor
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific
EQS-News: Knorr-Bremse acquires duagon Group, enhancing growth of global rail business
EQS-Adhoc: Knorr-Bremse Aktiengesellschaft: Knorr-Bremse acquires duagon Group, enhancing growth of global rail business
EQS-News: Verbio SE: Verbio confirms preliminary EBITDA result for 2024/25 and expects significant recovery in FY 2025/26
EQS-News: Verbio SE: Verbio confirms preliminary EBITDA result for 2024/25 and expects significant recovery in FY 2025/26
EQS-News: Energiekontor AG: Energiekontor puts Königsfeld solar park into operation and expands own portfolio – PPA cooperation with Currenta ensures sustainable energy supply in the chemical sector
EQS-Adhoc: Verbio SE: Suspension of dividend for the financial year 2024/25
EQS-Adhoc: Verbio SE: Suspension of dividend for the financial year 2024/25
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of
EQS-Adhoc: Porsche Automobil Holding SE: Adjustment of the forecast for the adjusted group result after tax 2025
EQS-News: Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
EQS-News: Eckert & Ziegler Gains Approval for GalliaPharm® in Japan